Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme

Journal of the National Cancer Institute

Volumn 91, Issue 17, 1999, Pages 1501-1504

  Milas, Luka ^a   Kishi, Kazushi ^a   Hunter, Nancy ^a   Mason, Kathryn ^a   Masferrer, Jaime L ^b   Tofilon, Philip J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Pharma Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN;

ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GAMMA RADIATION; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE;

EID: 0033199927     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.17.1501     Document Type: Article

References (24)

1. Moskowitz MA, Coughlin SR. Clinical applications of prostaglandins and their inhibitors. Stroke 1981;12:882-6.
2. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999;91:22-36.
3. Leung KH, Mihich E. Prostaglandin modulation of development of cell-mediated immunity in culture. Nature 1980;288: 597-600.
4. Brunda MJ, Herberman RB, Holden HT. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 1980;124: 2682-7.
5. Honn KV, Bockman RS, Marnett LJ. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins 1981;21:833-64.
6. Furuta Y, Hall ER, Sanduja S, Barkley T Jr, Milas L. Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res 1988;48: 3002-7.
7. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998;90:1609-20.
8. Milas L, Hanson WR. Eicosanoids and radiation. Eur J Cancer 1995;31A:1580-5.
9. Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors: a new class of antiinflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996;25:363-72.
10. Furuta Y, Hunter N, Barkley T Jr, Hall E, Milas L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 1988;48:3008-13.
11. Milas L, Furuta Y, Hunter N, Nishiguchi I, Runkel S. Dependence of indomethacin-induced potentiation of murine tumor radio-response on tumor host immunocompetence. Cancer Res 1990;50:4473-7.
12. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529-36.
13. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998;280:1268-70.
14. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1.5-dairylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(5-methylphenyl)-3-(trifluoromethyl)-1 H-pyrazoll-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-65.
15. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91: 12013-7.
16. Herson J. Fieller's theorem vs. the Delta method for significance intervals for ratios. J Statist Comput Simul 1975;3: 265-74.
17. 1 and copper in angiogenesis. J Natl Cancer Inst 1982;69:475-82.
18. Runkel S, Hunter N, Milas L. An intradermal assay for quantification and kinetics studies of tumor angiogenesis in mice. Radiat Res 1991;126:237-43.
19. Milas L, Wike J, Hunter N, Volpe J, Basic I. Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability. Cancer Res 1987;47:1069-75.
20. 2 induces radioprotection in murine intestinal and hematopoietic stem cells. Radiat Res 1985;103:196-203.
21. Hanson WR, Jarnagin W, De Lauetiis K, Malkinson RD. Modification of radiation injury of murine intestinal clonogenic cells and B-16 melanoma by PGI2 or flurbiprofen. In: Walden TL, Hughes HN, editors. Prostaglandin and lipid metabolism in radiation injury. New York (NY): Plenum Press; 1987. p 331-8.
22. Masferrer JM, Leahy JM, Lei Y, Moore R, Flickinger A, Zwefel B, et al. Celecoxib: a specific cox-2 inhibitor with anti-angiogenic and anti-cancer activities [abstract]. Proc Am Assoc Cancer Research 1999;40:396.
23. Gorski DH, Mauceri H, Salloum RM, Gately S, Hellman S, Beckett MA, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686-9.
24. Finney DJ. Quantal response and the tolerance distribution. Statistical methods in biological assay. 2nd ed. London (U.K.): Griffen; 1952.